PINX1 and non-small cell lung carcinoma: Notably, cells deficient in PinX1 benefit from a combination treatment with RT or radioimmunotherapy, suggesting a potential role for targeting telomeres/telomerase in radioimmunotherapy, which may help the development of individualized strategies for the treatment of NSCLC (Additional file 7).